Drug Trial Radar · NCT00659789
Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected With HIV
Last checked: Nov 19, 2026Latest source record: Feb 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
137
Actual
Start
Aug 2008
Primary completion
Jun 2010
Study completion Jun 2011
Sponsor
- Lead sponsor
- Bionor Immuno ASIndustry
- Sponsor type
- Industry
- First posted
- Apr 16, 2008
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Current management of HIV infection includes anti-retroviral therapy (ART). ART cannot cure the infection, making it a life-long treatment that requires sustained patient compliance and imposes significant individual and societal financial burdens on healthcare services. Furthermore, ART side effects often require medication that increases the inconveniences and financial burdens of HIV management. Of further concern is the emergence of viruses resistant to ART that can result in treatment failure. ART-free periods could provide substantial benefit. Vacc-4x is a peptide-based HIV immunotherapy that is proposed for prolongation of ART-free periods. The purpose of this study is to determine whether Vacc-4x immunotherapy can give safe ART-free period.
Conditions
- HIV I Infection
Interventions
Vacc-4xDrug
Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
Sterile waterDrug
Sterile water is used in place of Vacc-4x and in place of Leukine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Subjects Who Require Resumption of ART Between the Interruption of ART at Week 28 and End of Study at Week 52.Time frame: From Week 28 to Week 52
Locations
18 sites in 5 countries. Site status is shown where the registry gives one.
UCLA CARE Center
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
UC Davis Medical Center
Sacramento, California
University of Miami School of Medicine
Miami, Florida
Northwestern University Division of Infectious Diseases
Chicago, Illinois
Universitätsklinikum Bonn
Bonn, Germany
Klinik I für Innere Medizin Klinikum Der Universität zu Köln
Cologne, Germany
ifi - Studien und Projekte GmbH, an der Asklepios-Klinik St. George
Hamburg, Germany
Universitätsklinikum Hamburg Eppendorf
Hamburg, Germany
EPIMED GmbH
Berlin, State of Berlin, Germany
Charité Universitätsmedizin Berlin
Berlin, State of Berlin, Germany
Istituto San Raffaele
Milan, Italy
Hospital Germans Trias i Pujol
Badalona, Spain
Hospital Clinic i Provincial
Barcelona, Spain
Unidad de VIH, Hospital de Bellvitge, Calle Feixa Llarga s/n, Hospitalet de Llobregat.
Barcelona, Spain
Brighton and Sussex University Hospital, HIV/GUM Research, Elton John Centre
Brighton, United Kingdom
Chelsea and Westminster Hospital
London, United Kingdom
Harrison Wing St Thomas' Hospital
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.